{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"Adverse Event is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.","groups":[{"description":"Ixazomib 3.0 mg, capsule, orally on Day 1 of Part A (15-day PK cycle) and on Days 1, 8, and 15 of each 28-day cycle in Part B (4.0, 3.0, or 2.3 mg per protocol) until disease progression or unacceptable toxicity.","id":"OG000","title":"Normal Renal Function: Ixazomib"},{"description":"Ixazomib 3.0 mg, capsule, orally on Day 1 of Part A (15-day PK cycle) and on Days 1, 8, and 15 of each 28-day cycle in Part B (4.0, 3.0, or 2.3 mg per protocol) until disease progression or unacceptable toxicity.","id":"OG001","title":"Severe Renal Impairment: Ixazomib"},{"description":"Ixazomib 3.0 mg, capsule, orally on Day 1 of Part A (15-day PK cycle) and on Days 1, 8, and 15 of each 28-day cycle in Part B (4.0, 3.0, or 2.3 mg per protocol) until disease progression or unacceptable toxicity.","id":"OG002","title":"End-stage Renal Disease: Ixazomib"}],"paramType":"NUMBER","populationDescription":"Safety population is defined as participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From signing of first dose of study drug up to the 30 days after the last dose of study drug (approximately up to 885 days)","title":"Number of Participants With Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}